Stealth BioTherapeutics patient/community update on MMPOWER-2 and RePOWER Primary Mitochondrial Myopathy clinical trials Stealth’s CEO Reenie McCarthy and Chief Clinical Development Officer Jim Carr shares updates on Stealth’s second clinical...
Exclusive Interview with Dr. Guy Miller, CEO of Edison Pharma. Is there hope for a cure for Mitochondrial Disease? Perhaps the answer is closer than we thought. On July...
Results from the Edison Pharma EPI-743 Phase 2A Leigh Syndrome Trial: An update with Dr. Guy Miller and Dr. Greg Enns
An update from Edison Pharma on the Development of EPI-743 clinical trial for children with Leigh Syndrome. Topics for this call include: Status on EPI-743 clinical development; Status on EPI-743...
Join us with Dr. Ben Bronstein and Travis Wilson from Stealth Peptides. Stealth Peptides is a private biotech company responsible for the development of innovative mitochondrial therapeutics, including the...
The nation’s leading mitochondrial disease patient advocacy organizations have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon...
Join us with Stealth BioTherapeutics CEO Travis Wilson and others from the Stealth BT team for a live update from Stealth BT (click here to check out their website), information about Bendavia, and details about StealthBioTherapeutics’ 2015 mitochondrial...
Greg Macpherson, CEO of MitoQ, discusses “Mitochondria and MitoQ: A Research Update.” MitoQ’s mission is to raise awareness of mitochondria and the link between optimal mitochondria function, health, and...